Compare Stocks: VACC, ACET, TELO, and IBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$6.35 -29.6%	$8.82	$6.01 ▼ $17.44	$84.44M	1.58	167,478 shs	2.13 million shs
IBIO iBio	$1.17 -1.7%	$1.35	$0.78 ▼ $3.82	$76.53M	1.29	631,331 shs	295,066 shs
TELO Telomir Pharmaceuticals	$1.20 -2.4%	$1.16	$0.89 ▼ $2.09	$84.59M	-0.25	69,518 shs	72,108 shs
VACC Vaccitech	$0.59 +8.9%	$1.57	$1.64 ▼ $5.10	$22.71M	-0.4	244,643 shs	25,243 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	-1.74%	-0.44%	+5.37%	-32.89%
IBIO iBio	0.00%	-7.03%	-12.50%	-31.21%	+118,999,900.00%
TELO Telomir Pharmaceuticals	0.00%	0.00%	+7.89%	-1.60%	-11.51%
VACC Vaccitech	0.00%	0.00%	0.00%	0.00%	-51.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$6.35 -29.6%	$8.82	$6.01 ▼ $17.44	$84.44M	1.58	167,478 shs	2.13 million shs
IBIO iBio	$1.17 -1.7%	$1.35	$0.78 ▼ $3.82	$76.53M	1.29	631,331 shs	295,066 shs
TELO Telomir Pharmaceuticals	$1.20 -2.4%	$1.16	$0.89 ▼ $2.09	$84.59M	-0.25	69,518 shs	72,108 shs
VACC Vaccitech	$0.59 +8.9%	$1.57	$1.64 ▼ $5.10	$22.71M	-0.4	244,643 shs	25,243 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	-1.74%	-0.44%	+5.37%	-32.89%
IBIO iBio	0.00%	-7.03%	-12.50%	-31.21%	+118,999,900.00%
TELO Telomir Pharmaceuticals	0.00%	0.00%	+7.89%	-1.60%	-11.51%
VACC Vaccitech	0.00%	0.00%	0.00%	0.00%	-51.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.88	Moderate Buy	$48.20	659.06% Upside
IBIO iBio	3.11	Buy	$5.29	351.77% Upside
TELO Telomir Pharmaceuticals	2.25	Hold	$4.00	233.33% Upside
VACC Vaccitech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VACC, ACET, TELO, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	ACET Adicet Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/28/2026	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$27.00 ➝ $34.00
9/21/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$27.00
9/17/2026	TELO Telomir Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/17/2026	TELO Telomir Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
9/1/2026	ACET Adicet Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	ACET Adicet Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/6/2026	ACET Adicet Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00 ➝ $90.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	N/A	N/A	N/A	N/A	$16.62 per share	N/A
IBIO iBio	$100K	752.43	N/A	N/A	$1.54 per share	0.76
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A
VACC Vaccitech	$13.42M	1.69	$0.03 per share	19.30	$6.52 per share	0.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	11/4/2026 (Estimated)
IBIO iBio	-$33.04M	-$0.34	N/A	N/A	N/A	N/A	-40.66%	-35.78%	11/11/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	12/2/2026 (Estimated)
VACC Vaccitech	$5.34M	-$1.43	N/A	N/A	N/A	-409.18%	-23.41%	-20.85%	N/A

Latest VACC, ACET, TELO, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q4 2026	IBIO iBio	-$0.0655	-$0.04	+$0.0255	-$0.07	$0.08 million	N/A
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VACC Vaccitech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	0.01	6.71	6.71
IBIO iBio	N/A	7.85	7.85
TELO Telomir Pharmaceuticals	N/A	16.16	16.16
VACC Vaccitech	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
IBIO iBio	7.90%
TELO Telomir Pharmaceuticals	N/A
VACC Vaccitech	26.13%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	3.40%
IBIO iBio	1.55%
TELO Telomir Pharmaceuticals	16.36%
VACC Vaccitech	6.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	102	9.36 million	9.04 million	Optionable
IBIO iBio	23	64.31 million	63.31 million	N/A
TELO Telomir Pharmaceuticals	5	68.78 million	57.52 million	N/A
VACC Vaccitech	33	38.55 million	36.23 million	Not Optionable

VACC, ACET, TELO, and IBIO Headlines

Recent News About These Companies

Vaccitech Announces Closing of $110.5 Million Initial Public Offering

July 14, 2026 | stockhouse.com

VTP-500 by Barinthus Biotherapeutics for Middle East Respiratory Syndrome (MERS): Likelihood of Approval

December 31, 2024 | pharmaceutical-technology.comP

Real-World Data on the RSV Vaccine for Older Adults

November 12, 2024 | msn.com

10 Startups Founded Out Of Oxford University

November 5, 2024 | techround.co.ukT

Ten things to know about new R21 malaria vaccine Nigeria received

October 18, 2024 | premiumtimesng.comP

Nigeria: Ten Things to Know About New R21 Malaria Vaccine Nigeria Received

October 18, 2024 | allafrica.com

Barinthus Bio completes enrolment in hepatitis B and prostate cancer vaccine trials

October 2, 2024 | finance.yahoo.com

Buy Rating Affirmed on Barinthus Biotherapeutics Amid Promising Clinical Trials and Therapeutic Advances

October 1, 2024 | markets.businessinsider.com

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

October 1, 2024 | markets.businessinsider.com

Strong Buy Rating for Barinthus Biotherapeutics Amid Promising Trials in Celiac and Hepatitis B Therapies

September 26, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical Advancements

August 12, 2024 | markets.businessinsider.com

BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024

August 9, 2024 | markets.businessinsider.com

Giving RSV and Flu Vaccines Together Led to Adequate Immune Responses

August 7, 2024 | medpagetoday.comM

How real are the threats to the US dollar?

July 31, 2024 | uk.finance.yahoo.com

Zoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market's Growth

July 29, 2024 | finance.yahoo.com

Google invests in UK vaccine pioneer Vaccitech

July 26, 2024 | pharmaphorum.comP

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

May 22, 2024 | markets.businessinsider.com

Buy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical Trials

May 17, 2024 | markets.businessinsider.com

Real reasons Nigeria still missing out on malaria vaccine rollout

May 11, 2024 | premiumtimesng.comP

Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout

May 3, 2024 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

VACC, ACET, TELO, and IBIO Company Descriptions

Adicet Bio NASDAQ:ACET

$6.35 -2.67 (-29.60%)

Closing price 04:00 PM Eastern

Extended Trading

$6.40 +0.05 (+0.83%)

As of 07:58 PM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

iBio NASDAQ:IBIO

$1.17 -0.02 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.01 (+0.77%)

As of 07:56 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Telomir Pharmaceuticals NASDAQ:TELO

$1.20 -0.03 (-2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$1.19 -0.01 (-0.83%)

As of 07:45 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Vaccitech NASDAQ:VACC

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VACC, ACET, TELO, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VACC, ACET, TELO, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VACC, ACET, TELO, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VACC, ACET, TELO, and IBIO Company Descriptions

Adicet Bio NASDAQ:ACET

iBio NASDAQ:IBIO

Telomir Pharmaceuticals NASDAQ:TELO

Vaccitech NASDAQ:VACC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VACC, ACET, TELO, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VACC, ACET, TELO, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VACC, ACET, TELO, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VACC, ACET, TELO, and IBIO Company Descriptions

Adicet Bio NASDAQ:ACET

iBio NASDAQ:IBIO

Telomir Pharmaceuticals NASDAQ:TELO

Vaccitech NASDAQ:VACC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools